CClinicalTrials.gg
CompletedNCT00091325Updated Jan 20, 2010

Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants

A Phase 1 interventional study of defined green tea catechin extract in Unspecified Adult Solid Tumor, Protocol Specific, sponsored by University of Arizona. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-01-20.

Sponsored by University of Arizona · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Study summary

RATIONALE: Green tea extract (Polyphenon E) contains ingredients that may prevent the development of cancer.

PURPOSE: This phase I trial is studying how well green tea extract works in preventing cancer in healthy participants.

Read the detailed description

OBJECTIVES:

Primary

  • Determine the effect of green tea extract (Polyphenon E) on cytochrome P450 enzyme activities and glutathione S-transferase activities and levels in healthy participants.

Secondary

  • Determine the safety and tolerability of this drug in these participants.

OUTLINE: This is an open-label study.

Participants receive oral green tea extract (Polyphenon E) once daily for 4 weeks in the absence of unacceptable toxicity.

Participants are followed for 2 weeks.

PROJECTED ACCRUAL: A total of 44 participants will be accrued for this study.

02

Conditions studied

  • Unspecified Adult Solid Tumor, Protocol Specific

Keywords

  • unspecified adult solid tumor, protocol specific
03

In context

Lead sponsor

University of Arizona is the lead sponsor of 466 studies on the registry; 87 are open to participants now.

Of its 47 completed or terminated interventional studies of FDA-regulated products, 29 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Healthy individuals

    • Non-smokers

      • More than 1 year since smoking cessation
      • No concurrent smokers
    • No regular consumption of large amounts of alcohol

      • On average, ≤ 3 alcoholic drinks per week
  • Consumes \< 6 cups or glasses of tea per week

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance Status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Bilirubin ≤ 2.0 mg/dL
  • AST or ALT ≤ 2 times normal
  • Alkaline phosphatase ≤ 2 times normal

Renal

  • Creatinine ≤ 1.5 mg/dL

Cardiovascular

  • Resting systolic blood pressure ≥ 100 mm Hg
  • No hypertension or hypercholesterolemia requiring unscheduled medical visits or changes in treatment within the past 3 months

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Willing to refrain from tea and related products and oral herbal/botanical supplements during study participation
  • Willing to limit the consumption of cruciferous vegetables to ≤ once a week during study participation
  • Willing to refrain from caffeine-containing food or beverages (e.g., coffee, colas, chocolate, or over-the-counter medications) for 72 hours before, during, and for 8 hours after study drug administration
  • Willing to refrain from food items that affect drug or carcinogen metabolizing enzymes (e.g., grapefruit, grapefruit juice, cruciferous vegetables, and food cooked over charcoal) for 72 hours before, during, and for 8 hours after study drug administration
  • No difficulty swallowing capsules or tablets
  • No metabolic disorder known to affect study drugs
  • No other serious acute or chronic disease (e.g., type I or II diabetes, cystic fibrosis, or active infection)
  • No known hypersensitivity to green tea or probe drugs (e.g., caffeine, dextromethorphan, losartan, or buspirone)
  • No invasive cancer (i.e., non-skin cancer) within the past 5 years

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • More than 3 months since prior participation in another clinical intervention study
  • No concurrent medications or supplements that are known P450 enzyme inducers or inhibitors
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Masking
None (open label)

Interventions

  • Dietary supplementdefined green tea catechin extract
06

Study locations

1 site
  • Arizona Cancer Center at University of Arizona Health Sciences Center
    Tucson, Arizona 85724, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00091325
Lead sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)
First posted
Sep 9, 2004
Start date
Oct 2004
Primary completion
Mar 2005
Last update
Jan 20, 2010

Study contacts

H. H. Sherry Chow, PhD
principal investigator · University of Arizona
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion